title: Infliximab in refractory psoriatic arthritis with severe psoriasis: a 2-year experience.
authors.forename: Paraskevi V
authors.initials: PV
authors.lastname: Voulgari
authors.forename: Aliki I
authors.initials: AI
authors.lastname: Venetsanopoulou
authors.forename: Efstratios K
authors.initials: EK
authors.lastname: Epagelis
authors.forename: Yannis
authors.initials: Y
authors.lastname: Alamanos
authors.forename: Ioanna
authors.initials: I
authors.lastname: Takalou
authors.forename: Alexandros A
authors.initials: AA
authors.lastname: Drosos
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D000069285:Infliximab; D007596:Joints / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy; D012867:Skin / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab